Hypericin - An inhibitor of proteasome function

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 5, 2005, Pages 439-446

  Pajonk, F ^a   Scholber, J ^a   Fiebich, B ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apoptosis; Hypericin; NF B; Proteasome; St. John's wort

Indexed keywords

CASPASE 3; CELL EXTRACT; HYPERICIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P50; SYNAPTOTAGMIN;

ARTICLE; BINDING AFFINITY; BREAST ADENOCARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; GLIOMA CELL; HUMAN; HUMAN CELL; INCUBATION TIME; PHOTOACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING;

ANTIDEPRESSIVE AGENTS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLIOMA; HUMANS; MAMMARY NEOPLASMS, ANIMAL; NF-KAPPA B; PERYLENE; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR CELLS, CULTURED;

EID: 17644392081     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0933-8     Document Type: Article

References (42)

1. Josey ES, Tackett RL (1999) St John's wort: a new alternative for depression? Int J Clin Pharmacol Ther 37(3): 111-119
2. Martin-Facklam M, Rieger K, Riedel KD, Burhenne J, Walter-Sack I, Haefeli WE (2004) Undeclared exposure to St John's wort in hospitalized patients. Br J Clin Pharmacol 58(4):437-441
3. Fiebich BL, Hoellig A, Lieb K (2001) Inhibition of substance P-induced cytokine synthesis by St John's wort extracts. Pharmacopsychiatry 34 [Suppl 1]:S26-S28
4. Fiebich BL, Heinrich M, Langosch JM, Kammerer N, Lieb K (1999) Antibacterial activity of hyperforin from St John's wort. Lancet 354(9180):777
5. Zou Y, Lu Y, Wei D (2004) Antioxidant activity of a flavonoidrich extract of Hypericum perforatum L. in vitro. J Agric Food Chem 52(16):5032-5039
6. Miskovsky P (2002) Hypericin - a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr Drug Targets 3(1):55-84
7. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss MH, Law RE, Apuzzo ML (1994) Hypericin: a potential antiglioma therapy. Neurosurgery 35(4):705-709 (discussion pp. 709-710)
8. Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K, Tamaoki T (1989) Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophys Res Commun 165(3):1207-1212
9. Bork PM, Bacher S, Schmitz ML, Kaspers U, Heinrich M (1999) Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med 65(4):297-300
10. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90(12):889-905
11. Assefa Z, Vantieghem A, Declercq W, Vandenabeele P, Vandenheede JR, Merlevede W, de Witte P, Agostinis P (1999) The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem 274(13):8788-8796
12. Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB, Moan J (2001) Intracellular localization of hypericin in human glioblastoma and carcinoma cell lines. Lasers Med Sci 16(4):276-283
13. Vantieghem A, Assefa Z, Vandenabeele P, Declercq W, Courtois S, Vandenheede JR, Merlevede W, de Witte P, Agostinis P (1998) Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett 440(1-2):19-24
14. Chaloupka R, Petit PX, Israel N, Sureau F (1999) Over-expression of Bcl-2 does not protect cells from hypericin photo-induced mitochondrial membrane depolarization, but delays subsequent events in the apoptotic pathway. FEBS Lett 462(3):295-301
15. Vantieghem A, Xu Y, Assefa Z, Piette J, Vandenheede JR, Merlevede W, De Witte PA, Agostinis P (2002) Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem 277(40):37718-37731
16. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663
17. Bremner P, Heinrich M (2002) Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54(4):453-472
18. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801-847
19. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78(5):773-785
20. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615-2622
21. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S (1999) Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 443(2):181-186
22. Zhang XM, Lin H, Chen C, Chen BD (1999) Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J 340(Pt 1):127-133
23. Schmidtke G, Holzhutter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, Groettrup M (1999) How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 274(50):35734-35740
24. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH (2002) The human immunodeficiency virus (HIV)-I protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62(18):5230-5235
25. Pajonk F, Pajonk K, McBride W (2000) Apoptosis and radiosensitization of Hodgkin's cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47(4):1025-1032
26. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL (1998) A proteolytic system that compensates for loss of proteasome function. Nature 392(6676):618-622
27. Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T, Saijo N (1999) Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 6(1):33-37
28. Schempp CM, Simon-Haarhaus B, Termeer CC, Simon JC (2001) Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8. FEBS Lett 493(1):26-30
29. Kang BY, Chung SW, Kim TS (2001) Inhibition of interleukin12 production in lipopolysaccharide-activated mouse macrophages by hypericin, an active component of Hypericum perforatum. Planta Med 67(4):364-366
30. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John's wort. Lancet 355(9203):547-548
31. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53(1):75-82
32. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94(16):1247-1249
33. Mannel M (2004) Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 27(11):773-797
34. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18(13):2505-2514
35. Leonard BE (2001) The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 25(4):767-780
36. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschutzky H, Jung G, Maier B, Eichmann K (1995) Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2(3):289-299
37. Pajonk F, Pajonk K, McBride WH (1999) Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91(22):1956-1960
38. Yang Y, Yu X (2003) Regulation of apoptosis: the ubiquitous way. FASEB J 17(8):790-799
39. Zhang W, Anker L, Law RE, Hinton DR, Gopalakrishna R, Pu Q, Gundimeda U, Weiss MH, Couldwell WT (1996) Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. Clin Cancer Res 2(5):843-846
40. Blank V, Kourilsky P, Israel A (1991) Cytoplasmic retention, DNA binding and processing of the NF-kappa B p50 precursor are controlled by a small region in its C-terminus. EMBO J 10(13):4159-4167
41. MacKichan ML, Logeat F, Israel A (1996) Phosphorylation of p105 PEST sequence via a redox-insensitive pathway up-regulates processing of p50 NF-kappaB. J Biol Chem 271(11):6084-6091
42. Kang KH, Lee KH, Kim MY, Choi KH (2001) Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis. J Biol Chem 276(27):24638-24644